Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 203, Issue 2, Pages 371-381Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20052242
Keywords
-
Categories
Funding
- NCI NIH HHS [P01 CA072009, P01 CA72009] Funding Source: Medline
- NIDDK NIH HHS [K01 DK062064, DK62064] Funding Source: Medline
Ask authors/readers for more resources
Mutations constitutively activating FLT3 kinase are detected in similar to 30% of acute myelogenous leukemia (AML) patients and affect downstream pathways such as extracellular signal-regulated kinase (ERK) 1/2. We found that activation of FLT3 in human AML inhibits CCAAT/enhancer binding protein alpha (C/EBP alpha) function by ERK1/2-mediated phosphorylation, which may explain the differentiation block of leukemic blasts. In MV4;11 cells, pharmacological inhibition of either FLT3 or MEK1 leads to granulocytic differentiation. Differentiation of MV4; 11 cells was also observed when C/EBP alpha mutated at serine 21 to alanine (S21A) was stably expressed. In contrast, there was no effect when serine 21 was mutated to aspartate (S21D), which mimics phosphorylation of C/EBP alpha. Thus, our results suggest that therapies targeting the MEK/ERK cascade or development of protein therapies based on transduction of constitutively active C/EBP alpha may prove effective in treatment of FLT3 mutant leukemias resistant to the FLT3 inhibitor therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available